198 related articles for article (PubMed ID: 37917177)
1. A molecular signature for IL-10-producing Th1 cells in protozoan parasitic diseases.
Edwards CL; Engel JA; de Labastida Rivera F; Ng SS; Corvino D; Montes de Oca M; Frame TC; Chauhan SB; Singh SS; Kumar A; Wang Y; Na J; Mukhopadhyay P; Lee JS; Nylen S; Sundar S; Kumar R; Engwerda CR
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37917177
[TBL] [Abstract][Full Text] [Related]
2. Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology.
Montes de Oca M; Kumar R; de Labastida Rivera F; Amante FH; Sheel M; Faleiro RJ; Bunn PT; Best SE; Beattie L; Ng SS; Edwards CL; Muller W; Cretney E; Nutt SL; Smyth MJ; Haque A; Hill GR; Sundar S; Kallies A; Engwerda CR
PLoS Pathog; 2016 Jan; 12(1):e1005398. PubMed ID: 26765224
[TBL] [Abstract][Full Text] [Related]
3. IL-10-producing Th1 cells possess a distinct molecular signature in malaria.
Edwards CL; Ng SS; de Labastida Rivera F; Corvino D; Engel JA; Montes de Oca M; Bukali L; Frame TC; Bunn PT; Chauhan SB; Singh SS; Wang Y; Na J; Amante FH; Loughland JR; Soon MS; Waddell N; Mukhopadhay P; Koufariotis LT; Johnston RL; Lee JS; Kuns R; Zhang P; Boyle MJ; Hill GR; McCarthy JS; Kumar R; Engwerda CR
J Clin Invest; 2023 Jan; 133(1):. PubMed ID: 36594463
[TBL] [Abstract][Full Text] [Related]
4. IL-27 signalling regulates glycolysis in Th1 cells to limit immunopathology during infection.
Montes de Oca M; de Labastida Rivera F; Winterford C; Frame TCM; Ng SS; Amante FH; Edwards CL; Bukali L; Wang Y; Uzonna JE; Kuns RD; Zhang P; Kabat A; Klein Geltink RI; Pearce EJ; Hill GR; Engwerda CR
PLoS Pathog; 2020 Oct; 16(10):e1008994. PubMed ID: 33049000
[TBL] [Abstract][Full Text] [Related]
5. The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani.
Rostan O; Gangneux JP; Piquet-Pellorce C; Manuel C; McKenzie AN; Guiguen C; Samson M; Robert-Gangneux F
mBio; 2013 Sep; 4(5):e00383-13. PubMed ID: 24045639
[TBL] [Abstract][Full Text] [Related]
6. Centrin-Deleted
Singh RK; Gannavaram S; Ismail N; Kaul A; Gedda MR; Nakhasi HL
Front Immunol; 2018; 9():1176. PubMed ID: 29915577
[TBL] [Abstract][Full Text] [Related]
7. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis.
Kemp M; Kurtzhals JA; Bendtzen K; Poulsen LK; Hansen MB; Koech DK; Kharazmi A; Theander TG
Infect Immun; 1993 Mar; 61(3):1069-73. PubMed ID: 8432588
[TBL] [Abstract][Full Text] [Related]
8. Genetically Modified Live Attenuated Leishmania donovani Parasites Induce Innate Immunity through Classical Activation of Macrophages That Direct the Th1 Response in Mice.
Bhattacharya P; Dey R; Dagur PK; Kruhlak M; Ismail N; Debrabant A; Joshi AB; Akue A; Kukuruga M; Takeda K; Selvapandiyan A; McCoy JP; Nakhasi HL
Infect Immun; 2015 Oct; 83(10):3800-15. PubMed ID: 26169275
[TBL] [Abstract][Full Text] [Related]
9. Distinct Roles for CD4
Bunn PT; Montes de Oca M; de Labastida Rivera F; Kumar R; Ng SS; Edwards CL; Faleiro RJ; Sheel M; Amante FH; Frame TCM; Muller W; Haque A; Uzonna JE; Hill GR; Engwerda CR
J Immunol; 2018 Dec; 201(11):3362-3372. PubMed ID: 30355785
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-21 Deficiency Promotes the Early Th1 Immune Response and Resistance toward Visceral Leishmaniasis.
Varikuti S; Verma C; Holcomb E; Jha BK; Viana A; Maryala R; Lamenza F; McElwain BK; Doni NY; Papenfuss T; Oghumu S; Gannavaram S; Nakhasi HL; Satoskar AR
J Immunol; 2021 Sep; 207(5):1322-1332. PubMed ID: 34341171
[TBL] [Abstract][Full Text] [Related]
11. CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene.
Ankathatti Munegowda M; Xu S; Freywald A; Xiang J
Mol Immunol; 2012 Jun; 51(2):143-9. PubMed ID: 22424785
[TBL] [Abstract][Full Text] [Related]
12. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4
Roessner PM; Llaó Cid L; Lupar E; Roider T; Bordas M; Schifflers C; Arseni L; Gaupel AC; Kilpert F; Krötschel M; Arnold SJ; Sellner L; Colomer D; Stilgenbauer S; Dietrich S; Lichter P; Izcue A; Seiffert M
Leukemia; 2021 Aug; 35(8):2311-2324. PubMed ID: 33526861
[TBL] [Abstract][Full Text] [Related]
13. Splenic CD4+ T Cells in Progressive Visceral Leishmaniasis Show a Mixed Effector-Regulatory Phenotype and Impair Macrophage Effector Function through Inhibitory Receptor Expression.
Medina-Colorado AA; Osorio EY; Saldarriaga OA; Travi BL; Kong F; Spratt H; Soong L; Melby PC
PLoS One; 2017; 12(1):e0169496. PubMed ID: 28103263
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 2 is an Upstream Regulator of CD4+ T Cells From Visceral Leishmaniasis Patients With Therapeutic Potential.
Chauhan SB; Faleiro R; Kumar R; Ng S; Singh B; Singh OP; Singh SS; Amante F; Rivera FL; Rai M; Chakravarty J; Sacks D; Nylen S; Sundar S; Engwerda C
J Infect Dis; 2019 Jun; 220(1):163-173. PubMed ID: 30796820
[TBL] [Abstract][Full Text] [Related]
15. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
16. Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.
Bhattacharya P; Dey R; Dagur PK; Joshi AB; Ismail N; Gannavaram S; Debrabant A; Akue AD; KuKuruga MA; Selvapandiyan A; McCoy JP; Nakhasi HL
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004963. PubMed ID: 27580076
[TBL] [Abstract][Full Text] [Related]
17. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
Choudhury R; Das P; De T; Chakraborti T
Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
[TBL] [Abstract][Full Text] [Related]
18. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA
Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354
[TBL] [Abstract][Full Text] [Related]
19. Combined Immune Therapy for the Treatment of Visceral Leishmaniasis.
Faleiro RJ; Kumar R; Bunn PT; Singh N; Chauhan SB; Sheel M; Amante FH; Montes de Oca M; Edwards CL; Ng SS; Best SE; Haque A; Beattie L; Hafner LM; Sacks D; Nylen S; Sundar S; Engwerda CR
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004415. PubMed ID: 26872334
[TBL] [Abstract][Full Text] [Related]
20. Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.
Gupta R; Kumar V; Kushawaha PK; Tripathi CP; Joshi S; Sahasrabuddhe AA; Mitra K; Sundar S; Siddiqi MI; Dube A
PLoS One; 2014; 9(1):e86073. PubMed ID: 24475071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
